Total Payments
$99,463
2024 Payments
$30,142
Companies
17
Transactions
138
Medicare Patients
767
Medicare Billing
$396,943
Payment Breakdown by Category
Consulting$76,974 (77.4%)
Other$7,500 (7.5%)
Travel$5,850 (5.9%)
Research$4,800 (4.8%)
Food & Beverage$4,164 (4.2%)
Education$175.04 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $76,974 | 24 | 77.4% |
| Travel and Lodging | $5,850 | 24 | 5.9% |
| Unspecified | $4,800 | 4 | 4.8% |
| Food and Beverage | $4,164 | 79 | 4.2% |
| Honoraria | $3,750 | 2 | 3.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750 | 3 | 3.8% |
| Education | $175.04 | 2 | 0.2% |
Payments by Type
General
$94,663
134 transactions
Research
$4,800
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $26,161 | 19 | $0 (2024) |
| Merz Pharmaceuticals, LLC | $21,089 | 6 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $14,757 | 12 | $0 (2023) |
| Lundbeck LLC | $9,541 | 8 | $0 (2022) |
| Novartis Pharma AG | $8,798 | 4 | $0 (2022) |
| ABBVIE INC. | $5,625 | 32 | $0 (2024) |
| Lilly USA, LLC | $3,573 | 6 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $3,161 | 15 | $0 (2018) |
| Amgen Inc. | $2,422 | 6 | $0 (2019) |
| Biogen, Inc. | $1,250 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,142 | 20 | Merz Pharmaceuticals, LLC ($21,089) |
| 2023 | $26,558 | 38 | PFIZER INC. ($17,787) |
| 2022 | $10,609 | 16 | Novartis Pharma AG ($8,798) |
| 2021 | $4,499 | 3 | Teva Pharmaceuticals USA, Inc. ($4,463) |
| 2020 | $1,529 | 3 | Lundbeck LLC ($1,500) |
| 2019 | $10,849 | 16 | Lundbeck LLC ($7,986) |
| 2018 | $823.04 | 12 | Allergan Inc. ($418.83) |
| 2017 | $14,455 | 30 | Teva Pharmaceuticals USA, Inc. ($6,962) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $3,200.00 | Research |
| Study: NURTEC CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 10/22/2024 | PFIZER INC. | NURTEC ODT (Drug) | Honoraria | Cash or cash equivalent | $2,250.00 | General |
| Category: PAIN | ||||||
| 10/17/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 08/28/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $4,612.50 | General |
| Category: Musculoskeletal | ||||||
| 08/28/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $2,050.00 | General |
| Category: Musculoskeletal | ||||||
| 08/28/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Travel and Lodging | Cash or cash equivalent | $54.39 | General |
| Category: Musculoskeletal | ||||||
| 08/28/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Travel and Lodging | Cash or cash equivalent | $22.03 | General |
| Category: Musculoskeletal | ||||||
| 08/15/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.72 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/17/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $7,175.00 | General |
| Category: Musculoskeletal | ||||||
| 07/17/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Consulting Fee | Cash or cash equivalent | $7,175.00 | General |
| Category: Musculoskeletal | ||||||
| 07/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 06/13/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| 04/22/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $109.90 | General |
| 04/09/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| 03/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: PAIN | ||||||
| 03/07/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $330.00 | Research |
| Study: RIMEGEPANT SULFATE ZAVEGEPANT MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 02/21/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | — | In-kind items and services | $330.00 | Research |
| Study: RIMEGEPANT SULFATE ZAVEGEPANT MULTI PRODUCT CLINICAL PUBLICATION PROGRAM • Category: PAIN | ||||||
| 02/08/2024 | PFIZER INC. | NURTEC ODT (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: PAIN | ||||||
| 01/05/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $70.84 | General |
| Category: Neuroscience | ||||||
| 12/08/2023 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Consulting Fee | Cash or cash equivalent | $2,997.50 | General |
| Category: Central Nervous System | ||||||
| 12/06/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: PAIN | ||||||
| 11/10/2023 | Ipsen Innovation | Dysport (Drug) | Food and Beverage | In-kind items and services | $162.95 | General |
| Category: Neurology | ||||||
| 11/10/2023 | Ipsen Innovation | Dysport (Drug) | Food and Beverage | In-kind items and services | $162.94 | General |
| Category: Neurology | ||||||
| 11/09/2023 | Ipsen Innovation | Dysport (Drug) | Travel and Lodging | In-kind items and services | $389.73 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NURTEC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| RIMEGEPANT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| RIMEGEPANT SULFATE ZAVEGEPANT MULTI PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $660.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 180 | 14,624 | $240,882 | $94,822 |
| 2022 | 7 | 212 | 16,680 | $287,187 | $109,385 |
| 2021 | 7 | 222 | 14,390 | $263,714 | $99,666 |
| 2020 | 6 | 153 | 14,757 | $240,162 | $93,072 |
Total Patients
767
Total Services
60,451
Medicare Billing
$396,943
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 29 | 14,400 | $144,000 | $71,416 | 49.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 29 | 73 | $48,472 | $10,324 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 75 | $22,425 | $7,342 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 40 | $11,960 | $2,522 | 21.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $11,130 | $2,397 | 21.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 15 | $2,895 | $818.82 | 28.3% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 29 | 16,402 | $162,805 | $79,559 | 48.9% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 29 | 87 | $57,768 | $12,223 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 40 | 61 | $18,239 | $5,943 | 32.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 28 | 30 | $15,900 | $3,540 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $11,220 | $3,005 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 40 | $11,960 | $2,609 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 18 | $3,474 | $1,129 | 32.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 12 | $3,312 | $735.30 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 13 | $2,509 | $640.63 | 25.5% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 27 | 14,100 | $141,000 | $68,288 | 48.4% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 29 | 82 | $54,448 | $11,598 | 21.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 37 | 37 | $19,610 | $4,428 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 41 | $12,259 | $4,363 | 35.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 29 | 41 | $7,913 | $3,259 | 41.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $10,560 | $2,942 | 27.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 18 | 26 | $7,774 | $2,128 | 27.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 34 | $6,562 | $1,844 | 28.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 13 | $3,588 | $815.23 | 22.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 31 | 14,573 | $146,180 | $70,688 | 48.4% |
About Teshamae Monteith
Teshamae Monteith is a Neurology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1972790186.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Teshamae Monteith has received a total of $99,463 in payments from pharmaceutical and medical device companies, with $30,142 received in 2024. These payments were reported across 138 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($76,974).
As a Medicare-enrolled provider, Monteith has provided services to 767 Medicare beneficiaries, totaling 60,451 services with total Medicare billing of $396,943. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Miami, FL
- Active Since 10/02/2007
- Last Updated 07/13/2011
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1972790186
Products in Payments
- Xeomin (Biological) $21,089
- AIMOVIG (Biological) $8,858
- NURTEC ODT (Drug) $8,084
- AJOVY (Biological) $7,493
- TEV-48125 (Biological) $6,304
- BOTOX (Biological) $5,201
- ZAVZPRET (Drug) $3,960
- TROKENDI XR (Drug) $3,142
- Aimovig (Biological) $2,422
- VYEPTI (Biological) $1,554
- Dysport (Drug) $1,105
- Zembrace (Drug) $634.65
- QULIPTA (Drug) $287.69
- UBRELVY (Drug) $236.14
- EMGALITY (Drug) $109.98
- Trudhesa (Drug) $70.74
- Vimpat (Drug) $34.50
- BOTOX THERAPEUTIC (Biological) $18.83
- OXTELLAR XR (Drug) $18.82
- ONZETRA Xsail (Drug) $17.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Miami
Dr. Diego Torres-Russotto, Md, MD
Neurology — Payments: $724,144
Neurology $724,144
Flavia Nelson, M.d, M.D
Neurology — Payments: $413,699
Neurology $413,699
Dr. Andrew Lerman, M.d, M.D
Neurology — Payments: $399,026
Neurology $399,026
Dr. Brad Herskowitz, M.d, M.D
Neurology — Payments: $301,062
Neurology $301,062
Dr. Kottil Rammohan, Md, MD
Neurology — Payments: $297,939
Neurology $297,939
Carlos Ramirez-Calderon, M.d, M.D
Neurology — Payments: $202,041
Neurology $202,041